Awaiting development: Guidance and quality standards

Showing 71 to 80 of 87

Guidance and quality standards awaiting development
Title	Type
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
Supporting independent living and preventing isolation in adults of working age with social care needs	Quality standard
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]	Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]	Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]	Technology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]	Technology appraisal guidance